| For: | Yuan SF, Li KZ, Wang L, Dou KF, Yan Z, Han W, Zhang YQ. Expression of MUC1 and its significance in hepatocellular and cholangiocarcinoma tissue. World J Gastroenterol 2005; 11(30): 4661-4666 [PMID: 16094706 DOI: 10.3748/wjg.v11.i30.4661] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v11/i30/4661.htm |
| Number | Citing Articles |
| 1 |
Anne Demols, Raphaël Maréchal, Jacques Devière, Jean-Luc Van Laethem. Biliary tract cancers: From pathogenesis to endoscopic treatment. Best Practice & Research Clinical Gastroenterology 2007; 21(6) doi: 10.1016/j.bpg.2007.09.005
|
| 2 |
Aldona Kasprzak, Agnieszka Adamek. Mucins: the Old, the New and the Promising Factors in Hepatobiliary Carcinogenesis. International Journal of Molecular Sciences 2019; 20(6) doi: 10.3390/ijms20061288
|
| 3 |
Shailendra K. Gautam, Parvez Khan, Gopalakrishnan Natarajan, Pranita Atri, Abhijit Aithal, Apar K. Ganti, Surinder K. Batra, Mohd W. Nasser, Maneesh Jain. Mucins as Potential Biomarkers for Early Detection of Cancer. Cancers 2023; 15(6) doi: 10.3390/cancers15061640
|
| 4 |
Monica Mossenta, Davide Busato, Michele Dal Bo, Paolo Macor, Giuseppe Toffoli. Novel Nanotechnology Approaches to Overcome Drug Resistance in the Treatment of Hepatocellular Carcinoma: Glypican 3 as a Useful Target for Innovative Therapies. International Journal of Molecular Sciences 2022; 23(17) doi: 10.3390/ijms231710038
|
| 5 |
Fei Cai, Yufan Gu, Jie Gao, Guanhua Yi, Yong Zhang. Key Mucins in Early Diagnosis of Pancreatic Ductal Adenocarcinoma and Biliary Tract Cancer: A Meta-Analysis. Phenomics 2026; doi: 10.1007/s43657-025-00288-9
|
| 6 |
Ayana R. Kumar, Aswathy R. Devan, Bhagyalakshmi Nair, Reshma Ravindran Nair, Lekshmi R. Nath. Biology, Significance and Immune Signaling of Mucin 1 in Hepatocellular Carcinoma. Current Cancer Drug Targets 2022; 22(9) doi: 10.2174/1568009622666220317090552
|
| 7 |
Udhayvir Singh Grewal, Razelle Kurzrock. Mucin-1: a promising pan-cancer therapeutic target. npj Precision Oncology 2025; 9(1) doi: 10.1038/s41698-025-01016-2
|
| 8 |
Kurinchi Gurusamy. Trace Element Concentration in Primary Liver Cancers—A Systematic Review. Biological Trace Element Research 2007; 118(3) doi: 10.1007/s12011-007-0008-x
|
| 9 |
Harriet Roddy, Tim Meyer, Claire Roddie. Novel Cellular Therapies for Hepatocellular Carcinoma. Cancers 2022; 14(3) doi: 10.3390/cancers14030504
|
| 10 |
QIONGSHU LI, FENGLI WANG, GUOMU LIU, HONGYAN YUAN, TANXIU CHEN, JUAN WANG, FEI XIE, RUIPING ZHAI, FANG WANG, YINGYING GUO, WEIHUA NI, GUIXIANG TAI. Impact of Mucin1 knockdown on the phenotypic characteristics of the human hepatocellular carcinoma cell line SMMC-7721. Oncology Reports 2014; 31(6) doi: 10.3892/or.2014.3136
|
| 11 |
Zhixiong Cai, Yongyi Zeng, Bo Xu, Yunzhen Gao, Sen Wang, Jinhua Zeng, Lihong Chen, Aimin Huang, Xiaolong Liu, Jingfeng Liu. Galectin‐4 serves as a prognostic biomarker for the early recurrence / metastasis of hepatocellular carcinoma. Cancer Science 2014; 105(11) doi: 10.1111/cas.12536
|
| 12 |
Kamonlapat Supimon, Thanich Sangsuwannukul, Jatuporn Sujjitjoon, Nattaporn Phanthaphol, Thaweesak Chieochansin, Naravat Poungvarin, Sopit Wongkham, Mutita Junking, Pa-thai Yenchitsomanus. Anti-mucin 1 chimeric antigen receptor T cells for adoptive T cell therapy of cholangiocarcinoma. Scientific Reports 2021; 11(1) doi: 10.1038/s41598-021-85747-9
|
| 13 |
J. Y. H. Chan, K. K. H. Lee, Y. L. Chui. Hilar Cholangiocarcinoma. 2013; doi: 10.1007/978-94-007-6473-6_10
|
| 14 |
Anjana Menon, Ayana R. Kumar, Mahima Bharathi, Adithya Jayaprakash Kamath, Asawari Dilip Donadkar, M. S. Sudheesh, Lekshmi R. Nath. Nanotechnology Based Strategies for Cancer Immunotherapy. 2024; doi: 10.1007/978-981-97-7022-9_9
|
| 15 |
O. E. Kuznetsov, V. M. Tsyrkunov, S. Sh. Kerimova. Mucin expression in liver cancer. Doklady of the National Academy of Sciences of Belarus 2023; 67(1) doi: 10.29235/1561-8323-2023-67-1-59-65
|
| 16 |
Giray Bozkaya, Peyda Korhan, Murat Çokaklı, Esra Erdal, Özgül Sağol, Sedat Karademir, Christopher Korch, Neşe Atabey. Cooperative interaction of MUC1 with the HGF/c-Met pathway during hepatocarcinogenesis. Molecular Cancer 2012; 11(1) doi: 10.1186/1476-4598-11-64
|
| 17 |
Pengfei Hao, Qi Li, Haoliang Zhao. Mucin 1 expression is regulated by hsa_circ_0055054/microRNA‑122‑5p and promotes hepatocellular carcinoma development. Oncology Letters 2024; 28(3) doi: 10.3892/ol.2024.14537
|
| 18 |
Xueyin Zhou, Bin Zhang, Jiahao Hu, Jiliang Shen, Zhehan Chen, Jinming Zhang, Bowen Wu, Enjie Zhou, Shuyou Peng, Tuck-Whye Wong, Guanjun Yang, Jiasheng Cao, Mingyu Chen. Igniting cold tumors of intrahepatic cholangiocarcinoma: An insight into immune evasion and tumor immune microenvironment. The Innovation Medicine 2024; 2(1) doi: 10.59717/j.xinn-med.2024.100052
|
| 19 |
Xinyu Shao. Immune microenvironment and progress in immunotherapy of cholangiocarcinoma. Clinical Immunology Communications 2023; 4 doi: 10.1016/j.clicom.2023.11.002
|
| 20 |
Parnaz Merikhian, Reyhane Ghadirian, Leila Farahmand, Sepideh Mansouri, Keivan Majidzadeh-A. MUC1 induces tamoxifen resistance in estrogen receptor-positive breast cancer. Expert Review of Anticancer Therapy 2017; 17(7) doi: 10.1080/14737140.2017.1340837
|
| 21 |
Tatsuya Murata, Ken Natsuga, Takuya Sho, Hideyuki Ujiie. Reticulated Erythematous Mucinosis Preceding the Clinical Diagnosis of Hepatitis C Virus–Related Hepatocellular Carcinoma. The Journal of Dermatology 2026; doi: 10.1111/1346-8138.70380
|
| 22 |
Neda Dadgar, Arun K. Arunachalam, Hanna Hong, Yee Peng Phoon, Jorge E. Arpi-Palacios, Melis Uysal, Chase J. Wehrle, Federico Aucejo, Wen Wee Ma, Jan Joseph Melenhorst. Advancing Cholangiocarcinoma Care: Insights and Innovations in T Cell Therapy. Cancers 2024; 16(18) doi: 10.3390/cancers16183232
|
| 23 |
Nicholas M. Riley, Ru M. Wen, Carolyn R. Bertozzi, James D. Brooks, Sharon J. Pitteri. Novel Methods and Pathways in Cancer Glycobiology Research. Advances in Cancer Research 2023; 157 doi: 10.1016/bs.acr.2022.09.001
|
| 24 |
Zixing Wang, Wenlong Xu, Haifeng Zhu, Yin Liu. A Bayesian Framework to Improve MicroRNA Target Prediction by Incorporating External Information. Cancer Informatics 2014; doi: 10.4137/CIN.S16348
|
| 25 |
Abdelfattah M. Attallah, Mohamed El-Far, Camelia A. Abdel Malak, Mohamed M. Omran, Khaled Farid, Raida S. Yahya, Entsar A. Saad, Mohamed S. Albannan, Ahmed A. Attallah, Mohamed A. El Basuni, Islam S. Ali, Safaa B. Abed, Mohamed A. El Naggar. A simple diagnostic index comprising epithelial membrane antigen and fibronectin for hepatocellular carcinoma. Annals of Hepatology 2015; 14(6) doi: 10.5604/16652681.1171774
|
| 26 |
Gi Jeong Kim, Hyungjin Rhee, Jeong Eun Yoo, Jung Eun Ko, Jee San Lee, Hyunki Kim, Jin Sub Choi, Young Nyun Park, Philip C. Trackman. Increased Expression of CCN2, Epithelial Membrane Antigen, and Fibroblast Activation Protein in Hepatocellular Carcinoma with Fibrous Stroma Showing Aggressive Behavior. PLoS ONE 2014; 9(8) doi: 10.1371/journal.pone.0105094
|
| 27 |
Kamonlapat Supimon, Thanich Sangsuwannukul, Jatuporn Sujjitjoon, Thaweesak Chieochansin, Mutita Junking, Pa-thai Yenchitsomanus. Cytotoxic activity of anti-mucin 1 chimeric antigen receptor T cells expressing PD-1-CD28 switch receptor against cholangiocarcinoma cells. Cytotherapy 2023; 25(2) doi: 10.1016/j.jcyt.2022.10.006
|
| 28 |
Hussein Mohsen, Kim Blenman, Prashant S. Emani, Quaid Morris, Jian Carrot-Zhang, Lajos Pusztai. Dynamic clustering of genomics cohorts beyond race, ethnicity—and ancestry. BMC Medical Genomics 2025; 18(1) doi: 10.1186/s12920-025-02154-z
|
| 29 |
Qiongshu Li, Guomu Liu, Hongyan Yuan, Juan Wang, Yingying Guo, Tanxiu Chen, Ruiping Zhai, Dan Shao, Weihua Ni, Guixiang Tai. Mucin1 shifts Smad3 signaling from the tumor-suppressive pSmad3C/p21WAF1 pathway to the oncogenic pSmad3L/c-Myc pathway by activating JNK in human hepatocellular carcinoma cells. Oncotarget 2015; 6(6) doi: 10.18632/oncotarget.2973
|
| 30 |
Hepatobiliary Cancers: Translational Advances and Molecular Medicine. Advances in Cancer Research 2022; 156 doi: 10.1016/bs.acr.2022.01.013
|
| 31 |
|
| 32 |
|
| 33 |
Watcharin Loilome, Hasaya Dokduang, Manida Suksawat, Sureerat Padthaisong. Therapeutic challenges at the preclinical level for targeted drug development for Opisthorchis viverrini-associated cholangiocarcinoma. Expert Opinion on Investigational Drugs 2021; 30(9) doi: 10.1080/13543784.2021.1955102
|
| 34 |
Keyur Patel, Ryan Lamm, Peter Altshuler, Hien Dang, Ashesh P. Shah. Hepatocellular Carcinoma—The Influence of Immunoanatomy and the Role of Immunotherapy. International Journal of Molecular Sciences 2020; 21(18) doi: 10.3390/ijms21186757
|
| 35 |
Mohammad Heiat, Hamid Hashemi Yeganeh, Seyed Moayed Alavian, Ehsan Rezaie. Immunotoxins Immunotherapy against Hepatocellular Carcinoma: A Promising Prospect. Toxins 2021; 13(10) doi: 10.3390/toxins13100719
|
| 36 |
AM Attallah, M El-Far, AR Ibrahim, MA El-desouky, MM Omran, MS Elbendary, KA Attallah, ER Qura, SO Abdallah. Clinical value of a diagnostic score for colon cancer based on serum CEA, CA19-9, cytokeratin-1 and mucin-1. British Journal of Biomedical Science 2018; 75(3) doi: 10.1080/09674845.2018.1456309
|
| 37 |
Ming Xu, Yang Pan. Chimeric Antigen Receptor (CAR)‐T Cells: A New Era for Hepatocellular Carcinoma Treatment. Journal of Biochemical and Molecular Toxicology 2024; 38(12) doi: 10.1002/jbt.70091
|
| 38 |
Stephen L. Chan, Angela Lamarca, Chiun Hsu, Victor Moreno, Landon L. Chan, Bridget P. Keenan. New targets and new drugs for hepatobiliary cancers. Journal of Hepatology 2026; 84(1) doi: 10.1016/j.jhep.2025.08.018
|
| 39 |
Ragini Singh, Ayush Sharma, Joel Saji, Akhela Umapathi, Santosh Kumar, Hemant Kumar Daima. Smart nanomaterials for cancer diagnosis and treatment. Nano Convergence 2022; 9(1) doi: 10.1186/s40580-022-00313-x
|
| 40 |
Abdelfattah M. Attallah, Mohamed El-Far, Sanaa O. Abdallah, Ahmed M. El-Waseef, Mohamed M. Omran, Mohamed A. Abdelrazek, Ahmed A. Attallah, Mohamed J. Saadh, Mohamed Radwan, Kholoud A. El-waffaey, Hassan Abol-Enei. Combined use of Epithelial Membrane Antigen and Nuclear Matrix Protein 52 as Sensitive Biomarkers for Detection of Bladder Cancer. The International Journal of Biological Markers 2015; 30(4) doi: 10.5301/jbm.5000164
|
| 41 |
Mohd-Akmal Hamizan, Mohd Afaque Ansari, Faheem Kareem, Minhaz Uddin Ahmed, Noor Faizah Mohd-Naim. Novel electrochemical aptasensor with AuNS/AuMR/PEI nanocomposite for ultrasensitive Mucin-1 detection. Electrochimica Acta 2026; 549 doi: 10.1016/j.electacta.2025.148091
|
| 42 |
Qiongshu Li, Guomu Liu, Dan Shao, Juan Wang, Hongyan Yuan, Tanxiu Chen, Ruiping Zhai, Weihua Ni, Guixiang Tai. Mucin1 mediates autocrine transforming growth factor beta signaling through activating the c-Jun N-terminal kinase/activator protein 1 pathway in human hepatocellular carcinoma cells. The International Journal of Biochemistry & Cell Biology 2015; 59 doi: 10.1016/j.biocel.2014.11.012
|
| 43 |
Abdelfattah M. Attallah, Sanaa O. Abdallah, Amr S. El Sayed, Mohamed M. Omran, Mahmoud El‐Bendary, Khaled Farid, Mohamed Kadry. Non‐invasive predictive score of fibrosis stages in chronic hepatitis C patients based on epithelial membrane antigen in the blood in combination with routine laboratory markers. Hepatology Research 2011; 41(11) doi: 10.1111/j.1872-034X.2011.00862.x
|
| 44 |
HONGYAN YUAN, JUAN WANG, FENGLI WANG, NANNAN ZHANG, QIONGSHU LI, FEI XIE, TANXIU CHEN, RUIPING ZHAI, FANG WANG, YINGYING GUO, WEIHUA NI, GUIXIANG TAI. Mucin 1 gene silencing inhibits the growth of SMMC-7721 human hepatoma cells through Bax-mediated mitochondrial and caspase-8-mediated death receptor apoptotic pathways. Molecular Medicine Reports 2015; 12(5) doi: 10.3892/mmr.2015.4323
|
| 45 |
Xiaoting Luo, Xin He, Xingmei Zhang, Xiaohui Zhao, Yuzhe Zhang, Yusheng Shi, Shengni Hua. Hepatocellular carcinoma: signaling pathways, targeted therapy, and immunotherapy. MedComm 2024; 5(2) doi: 10.1002/mco2.474
|
| 46 |
IpekIsik Gonul, Asli Cakir, Sinan Sozen. Immunohistochemical expression profiles of MUC1 and MUC2 mucins in urothelial tumors of bladder. Indian Journal of Pathology and Microbiology 2018; 61(3) doi: 10.4103/IJPM.IJPM_12_18
|
| 47 |
Thomas T DeLeon, Yumei Zhou, Bolni M Nagalo, Raquel T Yokoda, Daniel H Ahn, Ramesh K Ramanathan, Marcela A Salomao, Bashar A Aqel, Amit Mahipal, Tanios S Bekaii-Saab, Mitesh J Borad. Novel Immunotherapy Strategies for Hepatobiliary Cancers. Immunotherapy 2018; 10(12) doi: 10.2217/imt-2018-0024
|
| 48 |
Chameli Ratan, Dalia Cicily K. D, Bhagyalakshmi Nair, Lekshmi. R. Nath. MUC Glycoproteins: Potential Biomarkers and Molecular Targets for Cancer Therapy. Current Cancer Drug Targets 2021; 21(2) doi: 10.2174/1568009620666201116113334
|
| 49 |
Christopher D. Briggs, Christopher P. Neal, Christopher D. Mann, William P. Steward, Margaret M. Manson, David P. Berry. Prognostic molecular markers in cholangiocarcinoma: A systematic review. European Journal of Cancer 2009; 45(1) doi: 10.1016/j.ejca.2008.08.024
|
| 50 |
Davide Busato, Monica Mossenta, Lorena Baboci, Federica Di Cintio, Giuseppe Toffoli, Michele Dal Bo. Novel immunotherapeutic approaches for hepatocellular carcinoma treatment. Expert Review of Clinical Pharmacology 2019; 12(5) doi: 10.1080/17512433.2019.1598859
|
| 51 |
Zhang Guizhen, Ji Guanchang, Liu Liwen, Wang Huifen, Ren Zhigang, Sun Ranran, Yu Zujiang. The tumor microenvironment of hepatocellular carcinoma and its targeting strategy by CAR-T cell immunotherapy. Frontiers in Endocrinology 2022; 13 doi: 10.3389/fendo.2022.918869
|
| 52 |
Harmeet Malhi, Gregory J. Gores. Cholangiocarcinoma: Modern advances in understanding a deadly old disease. Journal of Hepatology 2006; 45(6) doi: 10.1016/j.jhep.2006.09.001
|